Evidence map›Paper›PMID 41309251›Full record

SynthesisZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Application and Progress of Organoid-on-a-chip Platforms 
in Lung Cancer Diagnosis and Therapy].

Wuyang Yun, Xiaoyun Zhang, Li Xiao

Abstract readEnglish AbstractSystematic ReviewReview
In one paragraph

Synthesis in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wuyang YunCollege of Pulmonary and Critical Care Medicine, Beijing Key Laboratory of Organ Transplantation and Immunology Regulatory, The 8th Medical Centre of Chinese PLA General Hospital, Beijing 100091, China.
Xiaoyun ZhangHebei North University, Zhangjiakou 075000, China.
Li XiaoCollege of Pulmonary and Critical Care Medicine, Beijing Key Laboratory of Organ Transplantation and Immunology Regulatory, The 8th Medical Centre of Chinese PLA General Hospital, Beijing 100091, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains one of the most prevalent and lethal malignancies worldwide. The advancement of its precise diagnosis and therapeutic development urgently requires in vitro models that can highly recapitulate the pathophysiological characteristics of human tissues. Organ-on-a-chip has emerged as a novel technological platform that integrates microfluidic engineering, biomaterials, and other engineering strategies with organoid culture. This platform enables precise control over the cellular microenvironment, thereby closely mimicking the three-dimensional structure and physiological functions of human organs in vitro. Organ-on-a-chip systems demonstrate significant advantages in cancer research, developmental biology, and disease modeling, as they not only preserve the heterogeneity and pathological features of patient samples but also support co-culture of various cell types to reconstruct the tumor microenvironment (TME). However, standardized construction methods and integrated analytical strategies for this technology in lung cancer research remain to be further refined. This review systematically elaborates on the key technical principles of organ-on-a-chip and its recent advances in lung cancer modeling, drug screening, and immunotherapy research. It aims to provide a theoretical foundation and technical perspective for promoting the deeper application of organ-on-a-chip in precision medicine and translational research for lung cancer.
.

Indexed as

Lab-On-A-Chip DevicesLung NeoplasmsOrganoidsAnimalsAntineoplastic AgentsDrug Screening Assays, AntitumorHumansImmunotherapyTumor MicroenvironmentAntineoplastic AgentsAntitumor drug screening assaysImmunotherapyLung neoplasmsOrganoidOrganoid-on-a-chip

Identifiers

PMID41309251
PMCPMC12666420

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.